The Occupational Exposure Limit (OEL) is defined as the airborne concentration of a substance (expressed as a weighted average in time for a working day of 8 hours/day and 40 hours/working week) under which it is believed that nearly all workers may be repeatedly exposed (day after day, over a working lifetime) without adverse health effects (ACGIH, 2006; DFG, 2005).
Occupational exposure limits (OELs) are a useful tool to prevent adverse effects on health when managing chemical substances.
On a European scale…
• Employers are legally obliged to provide a work environment that does not threaten the health of the workers (Chemical Agent Directive 98/24/EC and Framework Directive 89/391/EEC).
• Under Directive 89/391/EEC, OELs can be developed nationally, Indicative Occupational Exposure Limit Values (IOELVs).
The presentation was an overview of the GMP regulations specific to cleaning validation for medicine manufacturers. New guidelines for Health Based Exposure Limits were discussed along with common GMP deficiencies observed during TGA inspections.
An understanding on requirements to produce Hazardous Pharmaceutical Products. The concept of containment facility and practices are described in easy to understand fashion.
Technology Transfer and Scale-up in Pharmaceutical IndustryPranjalWagh1
Transfer of technology is defined as “a logical procedure that controls the transfer of any process together with its documentation and professional expertise between development and manufacture or between manufacture sites”.
In Pharmaceutical Industry, technology transfer refers to the processes that are needed for successful progress from drug discovery to product development to clinical trials to full scale commercialization.
It is basically divided into three phases - Research Phase, Development Phase and Production Phase. The presentation elaborates on the technology transfer taking place in production phase. Production phase mainly concerns with validation studies and scale-up.
Validation studies such as performance qualification, cleaning validation and process validation is carried out by R&D department.
Scale-up involves the use of results obtained from lab studies for designing prototype of a product and pilot plant process, constructing pilot plant and further using pilot plant data for full-scale commercialization.
The presentation was an overview of the GMP regulations specific to cleaning validation for medicine manufacturers. New guidelines for Health Based Exposure Limits were discussed along with common GMP deficiencies observed during TGA inspections.
An understanding on requirements to produce Hazardous Pharmaceutical Products. The concept of containment facility and practices are described in easy to understand fashion.
Technology Transfer and Scale-up in Pharmaceutical IndustryPranjalWagh1
Transfer of technology is defined as “a logical procedure that controls the transfer of any process together with its documentation and professional expertise between development and manufacture or between manufacture sites”.
In Pharmaceutical Industry, technology transfer refers to the processes that are needed for successful progress from drug discovery to product development to clinical trials to full scale commercialization.
It is basically divided into three phases - Research Phase, Development Phase and Production Phase. The presentation elaborates on the technology transfer taking place in production phase. Production phase mainly concerns with validation studies and scale-up.
Validation studies such as performance qualification, cleaning validation and process validation is carried out by R&D department.
Scale-up involves the use of results obtained from lab studies for designing prototype of a product and pilot plant process, constructing pilot plant and further using pilot plant data for full-scale commercialization.
the occupational exposure limit (OEL) represents the maximum airborne concentration of a toxic substance to which a worker can be exposed over a period of time without suffering any harmful consequences.
Setting Specification Limits for Impurities in Active Pharmaceutical Ingredient (API’s).
Setting Specification Limits for Impurities in Active Pharmaceutical Ingredient (API’s)
Setting Specification Limits for Impurities in Active Pharmaceutical Ingredient (API’s)
This presentation gives an idea about extractable and leachables, Analytical techniques used for conducting studies. importance of conducting E&L studies.
New guidelines relating to elemental impurities from the International Conference on Harmonization (ICH), Q3D Guideline for Elemental Impurities have presented the pharmaceutical industry with new challenges. This new guidance has been developed to provide a global policy for limiting metal impurities qualitatively and quantitatively in drug products and ingredients.
Environmental Monitoring describes the microbiological testing under- taken in order to detect changing trends of microbial counts and micro- flora growth within cleanroom or controlled environments. The results obtained provide information about the physical construction of the room, the performance of the Heating, Ventilation, and Air-Conditioning (HVAC) system, personnel cleanliness, gowning practices, the equipment, and cleaning operations.
Over the past decade, environmental monitoring has become more sophisticated in moving from random sampling, using an imaginary grid over the room and testing in each grid, to the current focus on risk assessment and the use of risk assessment tools to determine the most appropriate methods for environmental monitoring.
This presentation gives current trends in the application of risk assessment to the practice of environmental monitoring.
the occupational exposure limit (OEL) represents the maximum airborne concentration of a toxic substance to which a worker can be exposed over a period of time without suffering any harmful consequences.
Setting Specification Limits for Impurities in Active Pharmaceutical Ingredient (API’s).
Setting Specification Limits for Impurities in Active Pharmaceutical Ingredient (API’s)
Setting Specification Limits for Impurities in Active Pharmaceutical Ingredient (API’s)
This presentation gives an idea about extractable and leachables, Analytical techniques used for conducting studies. importance of conducting E&L studies.
New guidelines relating to elemental impurities from the International Conference on Harmonization (ICH), Q3D Guideline for Elemental Impurities have presented the pharmaceutical industry with new challenges. This new guidance has been developed to provide a global policy for limiting metal impurities qualitatively and quantitatively in drug products and ingredients.
Environmental Monitoring describes the microbiological testing under- taken in order to detect changing trends of microbial counts and micro- flora growth within cleanroom or controlled environments. The results obtained provide information about the physical construction of the room, the performance of the Heating, Ventilation, and Air-Conditioning (HVAC) system, personnel cleanliness, gowning practices, the equipment, and cleaning operations.
Over the past decade, environmental monitoring has become more sophisticated in moving from random sampling, using an imaginary grid over the room and testing in each grid, to the current focus on risk assessment and the use of risk assessment tools to determine the most appropriate methods for environmental monitoring.
This presentation gives current trends in the application of risk assessment to the practice of environmental monitoring.
Cleaning validation a risk integrated approachSambhujyoti Das
A risk integrated Cleaning validation based on Acceptable Daily Exposure. The presentation is prepared on recent EMEA requirement of health based cleaning validation and contamination control for shared facilities. The practical cases are demonstrated in this presentation to better understanding on the subject.
Any suggestion is highly expected.
Guidance for Industry and Other StakeholdersToxicological Principles for the...Dmitri Popov
This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It
does not create or confer any rights for or on any person and does not operate to bind FDA or the public.
Choosing Chemicals for Precautionary Regulation: A Filter Series Approach (2005)morosini1952
Ulrich Müller-Herold, Marco Morosini, Olivier Schucht
Abstract
The present case study develops and applies a systematic
approach to the precautionary pre-screening of xenobiotic
organic chemicals with respect to large-scale environmental
threats. It starts from scenarios for uncontrollable harm
and identifies conditions for their occurrence that then are
related to a set of amplifying factors, such as characteristic
isotropic spatial range F. The amplifying factors related
to a particular scenario are combined in a pre-screening
filter. It is the amplifying factors that can transform a potential
local damage into a large-scale threat. Controlling the
amplifying factors means controlling the scope and range
of the potential for damage. The threshold levels for the
amplifying factors of each filter are fixed through recourse
to historical and present-day reference chemicals so as
to filter out as many as possible of the currently regulated
environmental chemicals and to allow the economically
important compounds that pose no large-scale environmental
concern. The totality of filters, with each filter corresponding
to a particular threat scenario, provides the filter series
to be used in precautionary regulation. As a demonstration,
the filter series is then applied to a group of nonreferential
chemicals. The case study suggests that the filter
series approach may serve as a starting point for
precautionary assessment as a scientific method of its
own.
Similar to Occupational exposure limits (OEL) to chemical agents APIs - Quantitative Risk Assessment (20)
Farmacovigilancia informe pass good vigilance practices (gvp) modulo viiiAzierta
La European Medicines Agency dedica el octavo de los módulos publicados sobre las buenas prácticas de farmacovigilancia (GVP) a los informes PASS. En 2016 entró en vigor la última revisión de este documento para incorporar nuevas exigencias que ya se han implementado. Con el fin de armonizar los estudios de seguridad post autorización (PASS) y su uso a nivel europeo, se definió una estructura tanto para el protocolo como para el informe final.
Se define un estudio de seguridad post autorización (PASS) como cualquier estudio relativo a un medicamento autorizado realizado con el fin de identificar, caracterizar o cuantificar un peligro para la seguridad, confirmando el perfil de seguridad del medicamento, o de medir la eficacia de las medidas de gestión de riesgos.
Existen dos tipos de informe: aquellos que son de conformidad con una obligación impuesta por una autoridad competente, o los No intervenciones realizados voluntariamente
Un estudio debe considerarse PASS cuando incluya los siguientes objetivos:
• cuantificar los riesgos potenciales o identificados
• evaluar los riesgos de un medicamento utilizado en una población de pacientes para la cual la información de seguridad es limitada o falta
• evaluar los riesgos de un medicamento después de un uso prolongado
• evaluar patrones de utilización de fármacos que aporten conocimientos sobre la seguridad del medicamento o la eficacia de una medida de gestión de riesgos
Los informes PASS tendrán un protocolo de estudio escrito, el cual debe ser desarrollado por personas con formación y experiencia científica apropiadas. El formato y protocolo de estudio de un informe PASS no es libre y está recogido en la EMA en el propio modulo.
Un informe PASS también ha de tener un informe final del estudio el cual seguirá el formato especifico descrito por la EMA y deberá presentarse dentro de los 12 meses siguientes al final de la recopilación. Si un estudio es suspendido, se debe presentar un informe final y se deben proporcionar las razones de suspensión del estudio.
En Azierta, Consultoría y Asesoría Científica, somos expertos en Farmacovigilancia y contamos con un equipo de especialistas altamente cualificado que da soporte a nuestros clientes de cara a gestionar la Farmacovigilancia de manera óptima. Nuestro trabajo cubre todos los ámbitos de la Farmacovigilancia, tanto a nivel de medicamentos como de productos sanitarios y cosméticos.
Si tienes interés en profundizar en los contenidos del módulo VIII de las GVP, así como en otros aspectos relacionados con la Farmacovigilancia, te invitamos a visitar el siguiente enlace donde podrás descargar gratuitamente documentación al respecto.
Ich q3d for elemental impurities risk evaluationAzierta
Directive ICH Q3D aims to limit the presence of potentially toxicelemental impurities (also known as heavy metals) in pharmaceutical products intended for human use.
This directive is linked to changes in the pharmacopoeias (Ph.Eur. & USP) with the introduction of new, safer, more selective and precise analytical methods with greater reproducibility and better recovery.
Likewise the directive establishes the toxicity limits of potentially present elements.
Directive ICH Q3D sets out a list of 24 elements divided into four categories (classes 1, 2A, 2B and 3), in relation to their toxicity and their probability of occurrence and the maximum permitted daily exposure (PDE: Permitted Daily Exposure) for each impurity according to the administration route (µg / day).
Development safety update report (dsur) pharmacovigilance and safetyAzierta
According to ICH guideline E2F (Step 5) on Development Safety Update Reports (DSURs) already implemented since 2011, companies must submit DSURs on a yearly basis for medicinal products involved in clinical trials. The focus of the DSUR is on data and findings from clinical trials of drugs and biologicals, whether they are authorized or not.
DSURs are internationally-harmonized, safety documents covering the safety summary of medicinal products during their development or clinical trial phase.
They are based heavily on the PSUR format already used for updating the safety record of drugs in their marketing phase.
A DSUR should be prepared after the first authorization of a clinical trial worldwide. A copy of the DSUR should be submitted to each concerned European Member State (MS) if a clinical trial is authorized in this MS for this investigational drug (still using the DIBD). Therefore, the first DSUR can be submitted to a concerned MS earlier than 1 year, but the covered reporting period should not be longer than 1 year.
The DSUR presents an annual review & evaluation of safety information:
• Information reported during the current review period and analysis based on previous knowledge of the products’ safety
• Description of new issues that may impact the overall program or specific clinical trials.
• Summarization of current understanding and management of known and potential safety risks to exposed patients.
• Provide an update on the status of the clinical development program.
In Azierta, scientific and healthcare consulting, we are experts in Pharmacovigilance and we have a team of highly qualified drug safety experts who support our clients to manage pharmacovigilance in an optimal way. Our work covers all areas of pharmacovigilance, both at the level of medicines, as well as medical devices and cosmetic products.
If you are interested in the contents of the good practices of pharmacovigilance (GVPs), as well as in other products related to pharmacovigilance visit our safety reports website for more details and feel free to contact us, we will be pleased to help you.
Safety reports rmp risk management plan pharmacovigilanceAzierta
A Risk management plan is a document based on safety profile of medicines that collects all pharmacovigilance activities and it is used to plan and implement measures in order to minimize risks.
This summary explains how to develop a Risk Management Plan according to European regulatory requirements.
Implementation dates and objectives of RMP module V of Good Pharmacovigilance Practices.
Evaluacion del riesgo cuantitativo (oel) y categorizacion de la exposicion oc...Azierta
El OEL (Occupational Exposure Limit) se define como la concentracion en el aire de una sustancia en la que se cree que casi todos los trabajadores podría exponerse sin efectos adversos.
Los limites de exposicion profesional (OEL) son un instrumento útil para la prevencion de los efectos en la salud durante el manejo de sustancias químicas.
Farmacovigilancia. Informe periodico de seguridad. periodic safety update rep...Azierta
El modulo VII de las GVP define como se debe realizar un PSUR, con el fin de actualizar el balance riesgo-beneficio de un medicamento.
Con estos módulos, la EMA busca garantizar la seguridad y eficacia de los medicamentos.
Safety reports. addendum to the clinical overview. acoAzierta
Critical discussion addressing the current benefit/risk balance for the product on the basis of a consolidated version of safety/efficacy data accumulated since the initial MA or the last renewal, taking into account PSURs submitted, suspected adverse reactions reports, additional pharmacovigilance activities and the effectiveness of risk minimization measures contained in the RMP, if applicable.
Then it is explained how to prepare an ACO according to European guidelines and following the required structure.
Farmacovigilancia gestión y desarrollo de informes individual safety case r...Azierta
Descripción del funcionamiento de la unidad de farmacovigilancia respecto a la gestión de casos clínicos. Repaso del módulo VI de las Good Vigilance Practices de la EMA.
Farmacovigilancia. RMP. Risk Management Plan. Good Pharmacovigilance Practice...Azierta
Descripción de un plan de gestion de riesgos o srisk management plan (RMP) donde se hace un repaso al modulo V de las guideline publicadas por la EMA.
Se ponen de manifiesto los objetivos que busca este organismo. Ademas se definen concetos importantes dentro de la farmacovigilancia y se evidencia cuándo es necesario desarrollar un RMP.
Por último, se explica detalladamente la estructura de un RMP.
Farmacovigilancia. Auditorías. Good Pharmacovigilance Practices (GVP). Módulo IVAzierta
Farmacovigilancia:
Auditorías en Farmacovigilancia
Good vigilance Practices (GVP)
Modulo IV
Azierta. Consultoría y asesoría científica. Farmacovigilancia España.
The aim of Safety reports is describe the safety during the lifecycle of the medicinal product. These reports are necessary during development as well as during the authorization process or renewal. In addition, several of these reports may be required by Health Authorities in case of safety concerns.
This presentation contains a full overview about periodic safety update reports and all the information related with it.
Casos de éxito en el desarrollo de innovadores y biosimilaresAzierta
Casos de éxito en el desarrollo de innovadores y biosimilares
Desarrollo de pequeñas moléculas de síntesis frente al desarrollo de biológicos/biosimilares
Oportunidades en el mercado biotecnologico: Medicamentos biologicos y biosimilares.
Repaso a los puntos críticos en el proceso de desarrollo y comercialización de medicamentos biologicos y biosimilares. Principales necesidades
Farmacovigilancia. Inspecciones. Good Pharmacovigilance Practices: Modulo IIIAzierta
Farmacovigilancia.
Inspecciones en Farmacovigilancia. Good vigilance practices (GVP) Modulo III.
Repaso general al modulo III de las GVP de la EMA. Diferencias entre auditorias e inspecciones, objetivos, tipos de inspecciones, flujo de actividades durante una inspección, y consejos prácticos a la hora de llevar a cabo una inspección.
Farmacovigilancia. Pharmacovigilance System Master File. Good Vigilance Pract...Azierta
Farmacovigilancia:
Pharmacovigilance System Master File (PSMF)
Archivo maestro de farmacovigilancia
Good vigilance Practices (GVP)
buenas practicas de farmacovigilancia
Azierta. Consultoría y asesoría científica. Farmacovigilancia España.
Farmacovigilancia Good Vigilance Practices I Sistemas de calidadAzierta
Good vigilance practices I.
Farmacovigilancia sistemas de calidad GVP I. Descripcion del modulo I de Buenas Practicas en Farmacovigilancia (GVP).
Aplicación de las normas ISO a las unidades de farmacovigilancia.
Formacion
Sistemas CAPA
Plan PDCA
Azierta. Consultoria y asesoria farmaceutica. Farmacovigilancia España
Farmacovigilancia: Vision general de la farmacovigilanciaAzierta
Farmacovigilancia:
Que es la farmacovigilancia. farmacovigilancia definicion. Farmacovigilancia concepto
GPV definiciones conceptos legislacion principios organismos. Repaso general sobre todos los temas relacionados con la farmacovigilancia:
Breve introducción sobre el concepto segun la OMS.
Evolución histórica y sucesos más importantes.
Conceptos y definiciones.
Metodología.
Organismos reguladores más importantes.
Legislación.
GVP: Good Vigilance Practices. Modulos sobre las buenas prácticas en farmacovigilancia y breve descripción de cada uno de ellos.
Conclusiones.
Azierta. Consultoria y asesoria farmaceutica. Farmacovigilancia España
Professional air quality monitoring systems provide immediate, on-site data for analysis, compliance, and decision-making.
Monitor common gases, weather parameters, particulates.
Toxic effects of heavy metals : Lead and Arsenicsanjana502982
Heavy metals are naturally occuring metallic chemical elements that have relatively high density, and are toxic at even low concentrations. All toxic metals are termed as heavy metals irrespective of their atomic mass and density, eg. arsenic, lead, mercury, cadmium, thallium, chromium, etc.
Salas, V. (2024) "John of St. Thomas (Poinsot) on the Science of Sacred Theol...Studia Poinsotiana
I Introduction
II Subalternation and Theology
III Theology and Dogmatic Declarations
IV The Mixed Principles of Theology
V Virtual Revelation: The Unity of Theology
VI Theology as a Natural Science
VII Theology’s Certitude
VIII Conclusion
Notes
Bibliography
All the contents are fully attributable to the author, Doctor Victor Salas. Should you wish to get this text republished, get in touch with the author or the editorial committee of the Studia Poinsotiana. Insofar as possible, we will be happy to broker your contact.
Slide 1: Title Slide
Extrachromosomal Inheritance
Slide 2: Introduction to Extrachromosomal Inheritance
Definition: Extrachromosomal inheritance refers to the transmission of genetic material that is not found within the nucleus.
Key Components: Involves genes located in mitochondria, chloroplasts, and plasmids.
Slide 3: Mitochondrial Inheritance
Mitochondria: Organelles responsible for energy production.
Mitochondrial DNA (mtDNA): Circular DNA molecule found in mitochondria.
Inheritance Pattern: Maternally inherited, meaning it is passed from mothers to all their offspring.
Diseases: Examples include Leber’s hereditary optic neuropathy (LHON) and mitochondrial myopathy.
Slide 4: Chloroplast Inheritance
Chloroplasts: Organelles responsible for photosynthesis in plants.
Chloroplast DNA (cpDNA): Circular DNA molecule found in chloroplasts.
Inheritance Pattern: Often maternally inherited in most plants, but can vary in some species.
Examples: Variegation in plants, where leaf color patterns are determined by chloroplast DNA.
Slide 5: Plasmid Inheritance
Plasmids: Small, circular DNA molecules found in bacteria and some eukaryotes.
Features: Can carry antibiotic resistance genes and can be transferred between cells through processes like conjugation.
Significance: Important in biotechnology for gene cloning and genetic engineering.
Slide 6: Mechanisms of Extrachromosomal Inheritance
Non-Mendelian Patterns: Do not follow Mendel’s laws of inheritance.
Cytoplasmic Segregation: During cell division, organelles like mitochondria and chloroplasts are randomly distributed to daughter cells.
Heteroplasmy: Presence of more than one type of organellar genome within a cell, leading to variation in expression.
Slide 7: Examples of Extrachromosomal Inheritance
Four O’clock Plant (Mirabilis jalapa): Shows variegated leaves due to different cpDNA in leaf cells.
Petite Mutants in Yeast: Result from mutations in mitochondrial DNA affecting respiration.
Slide 8: Importance of Extrachromosomal Inheritance
Evolution: Provides insight into the evolution of eukaryotic cells.
Medicine: Understanding mitochondrial inheritance helps in diagnosing and treating mitochondrial diseases.
Agriculture: Chloroplast inheritance can be used in plant breeding and genetic modification.
Slide 9: Recent Research and Advances
Gene Editing: Techniques like CRISPR-Cas9 are being used to edit mitochondrial and chloroplast DNA.
Therapies: Development of mitochondrial replacement therapy (MRT) for preventing mitochondrial diseases.
Slide 10: Conclusion
Summary: Extrachromosomal inheritance involves the transmission of genetic material outside the nucleus and plays a crucial role in genetics, medicine, and biotechnology.
Future Directions: Continued research and technological advancements hold promise for new treatments and applications.
Slide 11: Questions and Discussion
Invite Audience: Open the floor for any questions or further discussion on the topic.
Richard's aventures in two entangled wonderlandsRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
What is greenhouse gasses and how many gasses are there to affect the Earth.moosaasad1975
What are greenhouse gasses how they affect the earth and its environment what is the future of the environment and earth how the weather and the climate effects.
The ability to recreate computational results with minimal effort and actionable metrics provides a solid foundation for scientific research and software development. When people can replicate an analysis at the touch of a button using open-source software, open data, and methods to assess and compare proposals, it significantly eases verification of results, engagement with a diverse range of contributors, and progress. However, we have yet to fully achieve this; there are still many sociotechnical frictions.
Inspired by David Donoho's vision, this talk aims to revisit the three crucial pillars of frictionless reproducibility (data sharing, code sharing, and competitive challenges) with the perspective of deep software variability.
Our observation is that multiple layers — hardware, operating systems, third-party libraries, software versions, input data, compile-time options, and parameters — are subject to variability that exacerbates frictions but is also essential for achieving robust, generalizable results and fostering innovation. I will first review the literature, providing evidence of how the complex variability interactions across these layers affect qualitative and quantitative software properties, thereby complicating the reproduction and replication of scientific studies in various fields.
I will then present some software engineering and AI techniques that can support the strategic exploration of variability spaces. These include the use of abstractions and models (e.g., feature models), sampling strategies (e.g., uniform, random), cost-effective measurements (e.g., incremental build of software configurations), and dimensionality reduction methods (e.g., transfer learning, feature selection, software debloating).
I will finally argue that deep variability is both the problem and solution of frictionless reproducibility, calling the software science community to develop new methods and tools to manage variability and foster reproducibility in software systems.
Exposé invité Journées Nationales du GDR GPL 2024
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Sérgio Sacani
We characterize the earliest galaxy population in the JADES Origins Field (JOF), the deepest
imaging field observed with JWST. We make use of the ancillary Hubble optical images (5 filters
spanning 0.4−0.9µm) and novel JWST images with 14 filters spanning 0.8−5µm, including 7 mediumband filters, and reaching total exposure times of up to 46 hours per filter. We combine all our data
at > 2.3µm to construct an ultradeep image, reaching as deep as ≈ 31.4 AB mag in the stack and
30.3-31.0 AB mag (5σ, r = 0.1” circular aperture) in individual filters. We measure photometric
redshifts and use robust selection criteria to identify a sample of eight galaxy candidates at redshifts
z = 11.5 − 15. These objects show compact half-light radii of R1/2 ∼ 50 − 200pc, stellar masses of
M⋆ ∼ 107−108M⊙, and star-formation rates of SFR ∼ 0.1−1 M⊙ yr−1
. Our search finds no candidates
at 15 < z < 20, placing upper limits at these redshifts. We develop a forward modeling approach to
infer the properties of the evolving luminosity function without binning in redshift or luminosity that
marginalizes over the photometric redshift uncertainty of our candidate galaxies and incorporates the
impact of non-detections. We find a z = 12 luminosity function in good agreement with prior results,
and that the luminosity function normalization and UV luminosity density decline by a factor of ∼ 2.5
from z = 12 to z = 14. We discuss the possible implications of our results in the context of theoretical
models for evolution of the dark matter halo mass function.
4. INTRODUCTION
The Occupational Exposure Limit (OEL) is defined as the airborne concentration of a
substance (expressed as a weighted average in time for a working day of 8 hours/day
and 40 hours/working week) under which it is believed that nearly all workers may
be repeatedly exposed (day after day, over a working lifetime) without adverse
health effects (ACGIH, 2006; DFG, 2005).
Occupational exposure limits (OELs) are a useful tool to prevent adverse effects on
health when managing chemical substances.
On a European scale…
• Employers are legally obliged to provide a work environment that does not
threaten the health of the workers (Chemical Agent Directive 98/24/EC and
Framework Directive 89/391/EEC).
• Under Directive 89/391/EEC, OELs can be developed nationally, Indicative
Occupational Exposure Limit Values (IOELVs).
4
5. INTRODUCTION
SOME LIMIT VALUES IN THE WORLD
• TLV ®(1950): Threshold Limit Value
American Conference of Governmental Industrial Hygienists (ACGIH)
• REL®: Recomended Exposure Limits
National Institute for Occupational Safety and Health (NIOSH)
• PEL®: Permissible Exposure Limits
Occupational Safety and Health Administration (OSHA)
• OEL®: Occupational Exposure Limits
Health and Safety Executive (HSE)
• VME®: Valeurs Moyennes d´Exposition
Institute National de la Recherche et la Securité (INRS)
• MAK®: Maximale Arbeitsplatzkoncentrationen
Deustche Forschungsgemeinschaft (DFG)
GESTIS - International limit values for chemical agents
5
8. RISK ASSESSMENT(ECETOC TR No. 101)
We calculate the OEL based on:
• Epidemiological studies or
• Toxicological data selecting the point of departure (POD) established by
repeated dosage studies in animals and applying appropriate correction
factors (ECETOC, 2003a) to take uncertainty and variability in the set of data
into account:
➢ NOAEL no-observed-adverse-effect level and
➢ LOAEL lowest-observed-adverse-effect level
8
9. RISK ASSESSMENT
9
D. A. Dankovic, B. D. Naumann et al. The Scientific Basis of Uncertainty Factors Used in Setting
Occupational Exposure Limits. J Occup Environ Hyg. 2015 Nov 25; 12(sup1): S55–S68.
10. RISK ASSESSMENT (ECETOC TR No. 101)
Relevant points to establish an OEL:
• Repeated dosage studies must last for at least 28 days.
• Toxicokinetic studies can provide information on the extent to which the
manner of exposure, distribution, metabolism and excretion of the substance
in animals are adequate to establish an OEL in humans.
• The criteria to select a NOAEL include the selection of the most relevant
species for man. If several studies are conducted with different species, the
highest NOAEL must be used, but this NOAEL must not exceed the LOAEL in
any of the other studies
10
11. RISK ASSESSMENT
Correction factors:
11
D. A. Dankovic, B. D. Naumann et al. The Scientific Basis of Uncertainty Factors Used in Setting Occupational
Exposure Limits. J Occup Environ Hyg. 2015 Nov 25; 12(sup1): S55–S68.
13. RISK ASSESSMENT
Correction factors:
• UFH : A value of 10 is normally used for the general population, in the absence of
specific chemical data.
• UFL : 1 (POD=NOAEL), 10 (POD=LOAEL)
• UFS : The purpose of OELs is to protect workers that are exposed throughout
their working life, in animals this is usually compared with a chronic study (e.g.
two (2) years for rats and mice).
13
D. A. Dankovic, B. D. Naumann et al. The Scientific Basis of Uncertainty Factors Used in Setting Occupational Exposure Limits.
J Occup Environ Hyg. 2015 Nov 25; 12(sup1): S55–S68.
14. RISK ASSESSMENT
UFD: 1-10. Incomplete toxicological data (studies of a single species, there are no
reproduction or development data, etc.)
Toxicokinetic (TK) adjustment:
Example: If an OEL is established from a critical effect in an oral study with a
bioavailability of 10%, bearing in mind that bioavailability for inhalation is 100%:
1.0/0.1 or a factor of 10.
Modification factor (MF): This factor is adjusted for uncertainties not tackled by
the UFs described above (<1 to 10).
14
D. A. Dankovic, B. D. Naumann et al. The Scientific Basis of Uncertainty Factors Used in Setting Occupational
Exposure Limits. J Occup Environ Hyg. 2015 Nov 25; 12(sup1): S55–S68.
15. RISK ASSESSMENT (ECETOC TR No. 101)
If there is no NOAEL/LOAEL:
• The maximum tolerated dose in long term studies can be used to establish an
OEL. If this is not known, the maximum tolerated dose can be predicted based
on acute oral toxicity (lethal dose in rats) and the octanol-water distribution
coefficient.
Molecules with a molecular mass of <500 and a Kow log of 0–4 are absorbed well
orally or by inhalation.
• Lethal concentrations of four hours of inhalation studies in rats can be
directly used to calculate the OEL.
15
16. RISK ASSESSMENT (ECETOC TR No. 101)
If there is no NOAEL/LOAEL:
• The use of QSARs to predict the toxicity is not reliable enough, therefore, they
are of limited value when it comes to establishing the OEL. It is better to look
for substances with similar structures and known toxicity (Read-across).
ChemIDplus (http://chem.sis.nlm.nih.gov/chemidplus/) (NLM, 2004).
• You can resort to the Threshold of Toxicological Concern (TTC), which is
normally used for food contaminants to determine the OEL by the most
conservative method. The first step in applying the TTC concept for a
particular substance is to identify the possible genotoxic effects and/or highly
potent carcinogens. If estimated intake does not exceed 1.5 μg / person / day,
you would not expect the substance to be a safety problem.
16
17. RISK ASSESSMENT (ECETOC TR No. 101)
At present, there are no procedures to establish the OELs for data-poor
substances.
Data poor substances: Substances that fall under Annex V of REACH (volume of
up to 10 t/year) form part of this category.
One possibility could be to use the derived-no-effect level (DNEL), taking this as
an OEL equivalent.
17
18. 18
Considerations to be taken into account:
• The absorption of a chemical substance is conditioned by:
➢ Physical state: Gas (inhalation), liquid (vapour inhalation, aerosol
droplets, directly through the skin), solid (aerosol inhalation)
➢ Temperature: When handling, during shipment, storage, etc.
➢ Dust of any type can become a hazardous substance when it is
present in airborne concentrations equal to or over 10 mg / m3 of
inhalable dust or 4 mg / m3 of respirable dust.
RISK ASSESSMENT (ECETOC TR No. 101)
19. 19
Considerations to be taken into account:
✓ The substance can also cause harm when:
• being absorbed through the skin;
• being ingested; or
• acting directly on the body at the point
of contact, e.g. the skin.
RISK ASSESSMENT (ECETOC TR No. 101)
20. 20
RESPIRATORY/SKIN/EYE IRRITANT AGENT
Because of its limited solubility in water, the substance may reach:
• The alveoli or
• Be inhaled as critically-sized particles ("respirable dust"),
The OEL must be based on the prevention of:
➢ Damage to the lung epithelium in the short term
➢ COPD, emphysema or pulmonary fibrosis after long-term exposure.
Contact with the skin can cause irritation and contact dermatitis. If a substance has
a high octanol-water partition coefficient and a low skin DL50, e.g. 1000 mg / kg,
the possibility of skin irritation must be considered.
RISK ASSESSMENT
21. 21
RESPIRATORY SENSITISER AGENT
A substance is considered to cause occupational asthma if, on account of exposure in
the workplace:
➢ It provokes a biological change known as a “hypersensitive state” in the
respiratory tracts; and
➢ It provokes a subsequent reaction in those respiratory tracts.
• Substances may not be hazardous in solid form but may indeed by so in fine
powder or dust form which can be inhaled into the lungs.
• Nanoparticles (<100 nanometres) can be more toxic than bigger ones of the same
substance.
• Impurities in a substance can make it more dangerous.
RISK ASSESSMENT
22. 22
SKIN SENSITISER AGENT
Allergic skin contact: Repeated exposure to a relatively low concentration.
There is a class of chemical substances that can cause allergic reactions in the skin
after exposure to sunlight or ultraviolet (UV) light. These chemical products are
known as photosensitisers.
Penetration of the skin can increase in highly humid settings. When temperatures
are high, perspiration can contribute to greater skin absorption.
RISK ASSESSMENT
23. 23
An adjusted OEL (AOEL) can be calculated when worker exposure time is not 8 hours a
day
RISK ASSESSMENT- AOELs
24. How is the OEL calculated in compounds?
Three possible compound cases are considered:
Synergistic substances: Quite uncommon. These are the most serious cases.
Additive substances: when there are reasons to believe that the effect of the
components are additive and are based on the same effects on health.
Independent substances: when the synergistic or additive effects are not known or
considered unlikely, the constituents can be considered as working independently and
the requisite measures are analysed to attain adequate control separately.
24
RISK ASSESSMENT- COMPOUNDS (ECETOC TR
No. 101)
25. 25
➢ If the total is < 1, exposure to the compound is below the OEL value
➢ If the total is > 1, exposure to the compound is above the OEL value
RISK ASSESSMENT- COMPOUNDS (ECETOC TR
No. 101)
Additive:
29. CATEGORIZATION SYSTEMS
Naumann et al., 1996:
• system based on five (5) categories
• range of permissible occupational exposure limits (PEL) that range from 1000 - 5000
μg/m3 in category 1 to those values under 100 ng/m3 in category 5.
Safebridge (SB) proposes, as does the ISPE
• a system based on four (4) categories
• a broader band range than in the previous case.
INSHT (NTP 798)
System based on five (5) categories
29
30. CATEGORIZATION SYSTEMS - AZIERTA
30
See the table in www.azierta.eu
Once the OEL value has been calculated and the toxicological analysis of the
substance carried out, a categorization of the substance shall be carried out taking
into account the toxicological and pharmacological characteristics as well as the
physicochemical properties of the substance.
31. In Azierta we are experts in Exposure Limits,
Categorization of APIs and Protocols of Health
Surveillance if you want to know us visit:
Azierta
Or follow us on :
Azierta
@Azierta